Neovasc’s Refractory Angina Treatment Receives CE Mark
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
Neovasc
Neovasc Aims For CE Mark in 2012
OneMedRadio interviewed Alexei Marko, CEO and Director of Neovasc [CVE:NVC] where he discussed the company’s products for treating heart disease. The company’s flagship product The Reducer is in late stage development.
More Than A Band-Aid For A Broken Heart: New Technology May Regenerate Failing Heart Tissue
For patients who have survived a heart attack, things get worse before they get better if they get better at all. Nearly 2 million people worldwide suffer from permanent heart damage due to lack of an appropriate therapy after a heart attack.